Event Description
Tremendous controversy surrounds the question of how to exercise effective oversight over cutting-edge biomedical technologies. At the federal level, past efforts have included presidentially appointed panels, NIH and FDA expert committees, and calls for legislation. Self-regulation by professional societies and litigation have also played a role. A participant in a number of the federal efforts, including the Human Embryo Research Panel, Prof. King reflected on what has worked and what has not, and what the lessons can be learned for future oversight.
Commentators
R. Scott McIvor, PhD
Department of Genetics, Cell Biology and Development
University of Minnesota
Rep. Phyllis Kahn, PhD, MPA
District 59B, Minnesota House of Representatives
Continuing Education Information
Continuing legal education credit (CLE) for attorneys (1.5 hours) was approved.